Key Takeaways:
- Illumina is accelerating NovaSeq X platform adoption across clinical markets, with over 65% of sequencing consumables revenue now driven by clinical applications, including oncology, rare disease, and prenatal testing.
- ILMN stock could reasonably reach $155 per share by December 2028, based on our valuation assumptions.
- This implies a total return of 22.2% from today’s price of $127, with an annualized return of 7.8% over the next 2.7 years.
What Happened?
Illumina, Inc. (ILMN) posted Q1 2026 revenue of $1.09 billion, up 4.8% year over year, with GAAP operating margin rising to 19.2% and GAAP diluted EPS increasing to $0.87. Adjusted EPS came in at $1.15, beating analyst estimates of around $1.05 by nearly 10%.
CEO Jacob Thaysen said, “Illumina delivered a strong start to 2026, reflecting the strength of the Illumina ecosystem and progress against our strategy.” The stock jumped 5.3% on April 30 in response to both the beat and the raised guidance, so investors greeted the news with genuine optimism.
NovaSeq X, Illumina’s flagship high-throughput sequencing instrument, saw more than 80 placements in Q1, which was around 20 more than the same period a year ago. Sequencing instruments are the machines that read DNA, and consumables are the chemical kits used each time the machine runs a test.
Clinical applications accounted for more than 65% of sequencing consumables revenue, while instrument performance obligations rose over 20%, with demand strongest in large centralized clinical labs across oncology, rare disease, and non-invasive prenatal testing. So clinical markets are clearly carrying the business while research spending remains cautious.
Illumina also noted it was supply-constrained on NovaSeq X in Q1 and is investing to scale supply, with improvement expected through Q2 and into Q3. That supply constraint is both a near-term headache and a strong demand signal.
Here’s why Illumina stock could continue to deliver above-market returns through 2028 as NovaSeq X adoption deepens and clinical markets drive durable earnings growth.
What the Model Says for ILMN Stock
We analyzed the upside potential for Illumina stock based on its accelerating NovaSeq X platform adoption, growing clinical sequencing volumes across oncology and rare disease, and the company’s expanding operating margin trajectory as the research market stabilizes over time.
Based on estimates of around 5% annual revenue growth, 25% operating margins, and a normalized P/E multiple of 23.4x, the model projects Illumina stock could rise from $127 to $155 per share.
That would be a 22.2% total return, or a 7.8% annualized return over the next 2.7 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for ILMN stock:
1. Revenue Growth: 5.3%
Illumina reported modest year-over-year revenue growth of 4.8% in Q1 2026 and beat Wall Street’s estimates by 1.8%. Clinical sequencing consumables grew about 20%, excluding China, representing more than 65% of total consumables revenue, while research and applied consumables declined amid funding uncertainty.
Looking ahead, sell-side analysts expect revenue to grow 4.6% over the next 12 months, below average for the sector. Management raised its 2026 revenue guidance to $4.52 billion to $4.62 billion, with acquired revenue from the SomaLogic transaction contributing 1.5 to 2 percentage points of growth and currency adding around 1%.
The company’s forward two-year revenue compound annual growth rate of 5% from the market data confirms a steady but not spectacular top-line trajectory.
Based on analysts’ consensus estimates, we used a 5.3% revenue growth forecast, slightly above the consensus, because it reflects the full-year benefit of NovaSeq X supply scaling and the continued clinical market migration.
2. Operating Margins: 25%
Illumina’s non-GAAP gross margin was 68.2% in Q1 2026, up 80 basis points year over year, driven by cost efficiencies and higher revenue, partly offset by tariff impacts. Non-GAAP operating margin came in at 21.9%, and management raised full-year non-GAAP operating margin guidance to a range of 23.4% to 23.6%.
The company has been an efficient operator over the last five years, maintaining average adjusted operating margins of around 22% even through the turbulent period following its failed GRAIL acquisition and subsequent separation. Non-GAAP operating expenses grew just 3% year over year in Q1, largely reflecting the addition of the SomaLogic team.
Based on analysts’ consensus estimates, we used a 25% operating margin, which aligns with the upper end of management’s 2026 guidance range and reflects the expected improvement in 2027 as the company continues its margin expansion journey.
3. Exit P/E Multiple: 23.4x
Illumina’s last-twelve-month P/E of 23.26x and its next-twelve-month P/E of 24.77x reflect the market’s pricing of a high-quality life sciences tools franchise with improving earnings quality. The company’s return on equity of 33.4% and gross margin of 68.2% confirm a business with genuine competitive advantages in sequencing technology and consumables.
The stock’s 52-week range of $73.86 to $155.53 reflects a wide range of sentiment over the past year, and so the current price of $127 sits well below the recent high. Illumina competes with Thermo Fisher Scientific and Agilent Technologies in life sciences tools, and it holds a dominant position in next-generation sequencing, the technology that reads DNA at high speed and scale.
Based on analysts’ consensus estimates, we use a 23.4x exit P/E, which matches the current last-twelve-month multiple and does not assume any multiple expansion. This is a neutral assumption because it uses today’s market valuation as the exit.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for ILMN stock through 2034 show varied outcomes based on NovaSeq X adoption pace, clinical market growth, and the recovery of research and applied spending (these are estimates, not guaranteed returns):
- Low Case: Research funding remains constrained, and China headwinds persist, limiting overall volume growth → around 3% annual returns
- Mid Case: Clinical volumes continue growing, and NovaSeq X penetration reaches management’s targets, while research slowly recovers → around 6% annual returns
- High Case: Spatial transcriptomics launches successfully, research spending recovers faster than expected, and margin expansion accelerates → around 8% annual returns
The near-term guided model shows a 7.8% annualized return through 2028, which is meaningfully higher than the decade-long mid-case IRR of around 5.8%, because the near-term assumptions reflect the current earnings momentum more directly.
The model’s return of 7.8% is below the 10% threshold that many investors consider highly attractive, so Illumina sits in a range that requires a conviction on the clinical growth story rather than a simple value argument.
The NovaSeq X platform’s supply ramp, the spatial transcriptomics launch, and the expected recovery in research markets are the three catalysts that investors will watch most closely through the rest of 2026 and into 2027.
See what analysts think about ILMN stock right now (Free with TIKR) >>>
Should You Invest in Illumina?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ILMN, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track ILMN alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Illumina stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
